EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Low Serum Levels of Myeloid Progenitor Inhibitory Factor-1 Predict Good Response to Methotrexate in Rheumatoid Arthritis

Varun Dhir, Amit Sandhu, Nidhi Gupta, Veena Dhawan, Shefali Sharma, Aman Sharma

ISRN Inflammation · 2013

DOI: 10.1155/2013/460469 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ISRN Inflammation, 2013. Verfasst von Varun Dhir und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine (Rheumatology Unit), Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Indian Rheumatology Association.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although the benchmark in the treatment of rheumatoid arthritis remains methotrexate, only 70% of patients respond. Thus, there is a need for predictive biomarkers. This study planned to evaluate serum levels of myeloid progenitor inhibitory factor-1 (MPIF-1) and monocyte chemoattractant protein 2 (MCP-2)—as biomarkers.

Methods

Patients with rheumatoid arthritis (RA) having high disease activity (DAS28-3v ≥ 5.1) were treated with oral methotrexate (MTX) for 12 weeks. Disease activity was measured by DAS28-3v (Modified Disease Activity Score 3 variables). Serum samples were stored at baseline and 12 weeks.

Results

This study included 46 patients (F : M = 35 : 11) having mean (±SD) age of 42.6 ± 11.3 yrs, disease duration of 4.7 ± 4.5 yrs, and DAS28-3v of 6.1 ± 0.8. Serum MPIF1 was elevated in patients compared to controls (1636.7 ± 1009.7, 441.2 ± 173.8 pg/mL, P < 0.001 ), but there was no difference in MCP2 levels (31.4 ± 11.9, 33.8 ± 24.0 pg/mL). Baseline MPIF-1 level was lower in good responders (ΔDAS28-3v ≥ 1.2, N = 9 ) compared to poor responders (ΔDAS28-3v < 0.6, N = 27 ) (1171.0 ± 670.8, 1816.7 ± 1154.1 pg/mL, P = 0.05 ). On ROC analysis, baseline MPIF1 performed reasonably to predict good response; that is, ΔDAS28-3v ≥ 1.2 (AUC 0.68, 95% CI 0.50–0.87).

Conclusions

Lower baseline MPIF1 level predicted a good response to methotrexate at 12 weeks.

Autor:innen und Institutionen

  • Department of Internal Medicine (Rheumatology Unit), Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India.
  • Department of Experimental Medicine and Biotechnology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India.

Förderung

  • Indian Rheumatology Association

Zitieren

APA

Dhir, V., Sandhu, A., Gupta, N., Dhawan, V., Sharma, S., & Sharma, A. (2013). Low Serum Levels of Myeloid Progenitor Inhibitory Factor-1 Predict Good Response to Methotrexate in Rheumatoid Arthritis. ISRN Inflammation. https://doi.org/10.1155/2013/460469

Vancouver

Dhir V, Sandhu A, Gupta N, Dhawan V, Sharma S, Sharma A. Low Serum Levels of Myeloid Progenitor Inhibitory Factor-1 Predict Good Response to Methotrexate in Rheumatoid Arthritis. ISRN Inflammation. 2013. doi:10.1155/2013/460469

BibTeX
@article{Dhir2013,
  author = {Dhir, Varun and Sandhu, Amit and Gupta, Nidhi and Dhawan, Veena and Sharma, Shefali and Sharma, Aman},
  title = {Low Serum Levels of Myeloid Progenitor Inhibitory Factor-1 Predict Good Response to Methotrexate in Rheumatoid Arthritis},
  journal = {ISRN Inflammation},
  year = {2013},
  doi = {10.1155/2013/460469}
}
Kostenlos starten →